Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes–focus on venlafaxine and O-desmethylvenlafaxine

被引：0
作者：
Mani Kandasamy
P. Srinivas
Kala Subramaniam
Sandhya Ravi
James John
Radha Shekar
Nuggehally Srinivas
Saral Thangam
机构：
[1] Lotus Labs,Biometrics
[2] Lotus Labs Pvt. Ltd.,Bioanalytical
[3] Lotus Labs Pvt. Ltd.,Clinical
[4] Suramas Biopharm,Drug Development
来源：
European Journal of Clinical Pharmacology | 2010年 / 66卷
关键词：
CYP2D6; Venlafaxine; O-desmethyvenlafaxine; Pharmacokinetics; Bioavailability;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：879 / 887
页数：8
相关论文
共 50 条
  • [21] CYP2D6*10 polymorphism and the enantioselective O-desmethylation of S-(+)- and R-(-)-venlafaxine in Japanese psychiatric patients
    Sasaki, Taro
    Yasui-Furukori, Norio
    Komahashi-Sasaki, Hazuki
    Shinozaki, Masataka
    Hayashi, Yuki
    Kato, Kazuko
    Inoue, Yoshimasa
    Tsuchimine, Shoko
    Watanabe, Takashi
    Sugawara, Norio
    Shimoda, Kazutaka
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2021, 128 (05) : 677 - 685
  • [22] Human CYP2D6 Is Functional in Brain In Vivo: Evidence from Humanized CYP2D6 Transgenic Mice
    Tolledo, Cole
    Stocco, Marlaina R.
    Miksys, Sharon
    Gonzalez, Frank J.
    Tyndale, Rachel F.
    MOLECULAR NEUROBIOLOGY, 2020, 57 (06) : 2509 - 2520
  • [23] Nifedipine Does Not Alter the Pharmacokinetics of Venlafaxine Enantiomers in Healthy Subjects Phenotyped for CYP2D6, CYP2C19, and CYP3A
    Tozatto, Eduardo
    Benzi, Jhohann Richard de Lima
    Rocha, Adriana
    Coelho, Eduardo Barbosa
    Lanchote, Vera Lucia
    JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (03) : 319 - 327
  • [24] Use of a propafenone metabolic ratio as a measure of CYP2D6 activity
    Anzenbacherová, E
    Anzenbacher, P
    Perlík, F
    Kvetina, J
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2000, 38 (09) : 426 - 429
  • [25] The Associations Between CYP2D6 Metabolizer Status and Pharmacokinetics and Clinical Outcomes of Venlafaxine: A Systematic Review and Meta-Analysis
    Lin, Xiao-Qian
    Wang, Ping
    Cai, Wen-Ke
    Xu, Gui-Li
    Yang, Mei
    Zhou, Meng-Di
    Sun, Mei
    He, Fang
    He, Gong-Hao
    PHARMACOPSYCHIATRY, 2019, 52 (05) : 222 - 231
  • [26] High-dose venlafaxine treatment in a depressed patient with a genetic CYP2D6 deficiency
    Haller-Gloor, F
    Eap, CB
    Turgeon, J
    Baumann, P
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2004, 8 (03) : 191 - 195
  • [27] Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans
    Lessard, É
    Yessine, MA
    Hamelin, BA
    O'Hara, G
    LeBlanc, J
    Turgeon, J
    PHARMACOGENETICS, 1999, 9 (04): : 435 - 443
  • [28] CYP2D6 gene polymorphisms and predicted phenotypes in eight indigenous groups from northwestern Mexico
    Patricia Lazalde-Ramos, Blanca
    de la Luz Martinez-Fierro, Margarita
    Galaviz-Hernandez, Carlos
    Garza-Veloz, Idalia
    Naranjo, Maria Eugenia G.
    Sosa-Macias, Martha
    LLerena, Adrian
    PHARMACOGENOMICS, 2014, 15 (03) : 339 - 348
  • [29] Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups
    Waade, Ragnhild Birkeland
    Hermann, Monica
    Moe, Hanne Lewis
    Molden, Espen
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 70 (08) : 933 - 940
  • [30] Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups
    Ragnhild Birkeland Waade
    Monica Hermann
    Hanne Lewis Moe
    Espen Molden
    European Journal of Clinical Pharmacology, 2014, 70 : 933 - 940
12345